SG11202000402PA - T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof - Google Patents
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereofInfo
- Publication number
- SG11202000402PA SG11202000402PA SG11202000402PA SG11202000402PA SG11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA SG 11202000402P A SG11202000402P A SG 11202000402PA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- methods
- receptor
- chimeric antigen
- deficient chimeric
- Prior art date
Links
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 230000002950 deficient Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762543735P | 2017-08-10 | 2017-08-10 | |
PCT/US2018/046137 WO2019032916A1 (fr) | 2017-08-10 | 2018-08-09 | Lymphocytes t récepteurs d'antigènes chimériques déficients en récepteurs de lymphocyte t et procédés d'utilisation correspondants |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000402PA true SG11202000402PA (en) | 2020-02-27 |
Family
ID=65231396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000402PA SG11202000402PA (en) | 2017-08-10 | 2018-08-09 | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
Country Status (10)
Country | Link |
---|---|
US (3) | US11648269B2 (fr) |
EP (1) | EP3665270A4 (fr) |
JP (1) | JP2020530291A (fr) |
KR (1) | KR20200035304A (fr) |
CN (1) | CN111247241A (fr) |
AU (1) | AU2018313939A1 (fr) |
CA (1) | CA3071282A1 (fr) |
SG (1) | SG11202000402PA (fr) |
WO (1) | WO2019032916A1 (fr) |
ZA (1) | ZA202000852B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
ES2839089T3 (es) | 2014-05-15 | 2021-07-05 | Nat Univ Singapore | Linfocitos citolíticos naturales modificados y usos de los mismos |
EP4134430A1 (fr) | 2015-02-06 | 2023-02-15 | National University of Singapore | Procédés d'amélioration de l'efficacité des cellules immunitaires thérapeutiques |
US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
US11365236B2 (en) | 2017-03-27 | 2022-06-21 | Nkarta, Inc. | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
US11648269B2 (en) | 2017-08-10 | 2023-05-16 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
JP2022512994A (ja) * | 2018-11-14 | 2022-02-07 | メディシックス セラピューティクス ピーティーイー リミテッド | Car-t細胞を生成する2遺伝子ベクターおよびその使用 |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
GB2605514A (en) * | 2019-10-11 | 2022-10-05 | Univ Leland Stanford Junior | Recombinant polypeptides for regulatable cellular localization |
CN113005088A (zh) * | 2019-12-19 | 2021-06-22 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
CN113088495A (zh) | 2020-01-09 | 2021-07-09 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
US20230355764A1 (en) * | 2020-09-13 | 2023-11-09 | Shandong Boan Biotechnology Co., Ltd. | Downregulation of membrane-bound proteins by receptor tac technology |
WO2024036285A2 (fr) * | 2022-08-11 | 2024-02-15 | Medisix Therapeutics, Inc. | Cellules immunitaires modifiées exprimant car et une pluralité de bloqueurs d'expression de protéine et leurs utilisations |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018248A1 (fr) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
JP2001516766A (ja) | 1997-09-19 | 2001-10-02 | デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫反応の細胞内発現抗体仲介制御 |
WO2003051926A2 (fr) | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Proteine de fusion anti-cd7 |
RU2404993C2 (ru) | 2003-07-02 | 2010-11-27 | Иннейт Фарма | Композиции и способы регуляции клеточной активности nk |
US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
WO2005017163A2 (fr) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Inactivation phenotypique de proteines de surface cellulaire |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
WO2006003179A2 (fr) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Anticorps anti-kir humains |
EP1814567A4 (fr) | 2004-10-27 | 2009-05-06 | Medimmune Inc | Utilisation de modulateurs de epha2 et de ephrina1 pour traiter et la prevenir des infections |
US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
CA2625998C (fr) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Anticorps anti-cd30 optimises |
JP5726417B2 (ja) | 2007-03-01 | 2015-06-03 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換え抗上皮成長因子受容体抗体組成物 |
WO2009033094A2 (fr) | 2007-09-07 | 2009-03-12 | Agensys, Inc. | Anticorps et molécules apparentées qui se lient aux protéines 24p4c12 |
CN101952317B (zh) | 2008-01-24 | 2015-07-22 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
DK2488867T3 (da) | 2009-10-14 | 2020-11-09 | Janssen Biotech Inc | Fremgangsmåder til affinitetsmodning af antistoffer |
WO2011059836A2 (fr) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
PL3214091T3 (pl) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów |
US20150202286A1 (en) | 2012-07-13 | 2015-07-23 | The Children's Hospital of Philadelphai | Toxicity Management for Anti-Tumor Activity of CARs |
JP6401704B2 (ja) | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス, インコーポレイテッド | T細胞を修飾する化合物およびその使用 |
KR101521224B1 (ko) | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
KR102160322B1 (ko) | 2012-12-27 | 2020-09-25 | 아두로 바이오테크, 인코포레이티드 | 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도 |
NZ750426A (en) | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
EP3858378A1 (fr) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cellule |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
EP3204491A1 (fr) | 2014-10-07 | 2017-08-16 | Cellectis | Procédé de modulation de l'activité des cellules immunitaires induite par un récepteur antigénique chimérique (car) |
EP3215168B1 (fr) | 2014-10-31 | 2023-08-02 | The Trustees of the University of Pennsylvania | Modification de l'expression génétique dans des lymphocytes t modifiés et utilisations associées |
US11091532B2 (en) | 2014-12-24 | 2021-08-17 | Autolus Limited | T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor |
EP4134430A1 (fr) | 2015-02-06 | 2023-02-15 | National University of Singapore | Procédés d'amélioration de l'efficacité des cellules immunitaires thérapeutiques |
EP3261651B1 (fr) * | 2015-02-27 | 2022-05-04 | iCell Gene Therapeutics LLC | Récepteurs d'antigène chimériques (car) ciblant des tumeurs malignes hématologiques, compositions et procédés pour les utiliser |
EP3089761B1 (fr) | 2015-03-02 | 2019-06-12 | Innovative Cellular Therapeutics Co., Ltd. | Réduction de la tolérance immunitaire induite par pd l1 |
JP2018520669A (ja) | 2015-06-19 | 2018-08-02 | マサチューセッツ インスティテュート オブ テクノロジー | 腫瘍免疫療法 |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
AU2016336451B2 (en) | 2015-10-06 | 2023-06-29 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
WO2017213979A1 (fr) | 2016-06-06 | 2017-12-14 | St. Jude Children's Research Hospital | Récepteur d'antigène chimérique anti-cd7 et son procédé d'utilisation |
JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体(CARs)の構成およびその使用方法 |
CA2937157A1 (fr) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Ecrasement de recepteur de cellule t fonde sur une proteine |
KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
GB201622044D0 (en) | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
CN110268050A (zh) | 2017-01-10 | 2019-09-20 | 综合医院公司 | 经修饰的t细胞和它们的使用方法 |
US11648269B2 (en) | 2017-08-10 | 2023-05-16 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
-
2018
- 2018-08-09 US US16/100,117 patent/US11648269B2/en active Active
- 2018-08-09 SG SG11202000402PA patent/SG11202000402PA/en unknown
- 2018-08-09 AU AU2018313939A patent/AU2018313939A1/en not_active Abandoned
- 2018-08-09 EP EP18844536.5A patent/EP3665270A4/fr not_active Withdrawn
- 2018-08-09 KR KR1020207006870A patent/KR20200035304A/ko not_active Application Discontinuation
- 2018-08-09 CA CA3071282A patent/CA3071282A1/fr active Pending
- 2018-08-09 WO PCT/US2018/046137 patent/WO2019032916A1/fr unknown
- 2018-08-09 JP JP2020506799A patent/JP2020530291A/ja active Pending
- 2018-08-09 CN CN201880057927.5A patent/CN111247241A/zh active Pending
- 2018-08-09 US US16/100,120 patent/US20190038733A1/en not_active Abandoned
-
2020
- 2020-02-10 ZA ZA2020/00852A patent/ZA202000852B/en unknown
-
2023
- 2023-04-03 US US18/295,226 patent/US20230364140A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3071282A1 (fr) | 2019-02-14 |
US20190046571A1 (en) | 2019-02-14 |
KR20200035304A (ko) | 2020-04-02 |
CN111247241A (zh) | 2020-06-05 |
WO2019032916A1 (fr) | 2019-02-14 |
EP3665270A1 (fr) | 2020-06-17 |
JP2020530291A (ja) | 2020-10-22 |
ZA202000852B (en) | 2023-10-25 |
AU2018313939A1 (en) | 2020-02-06 |
US20190038733A1 (en) | 2019-02-07 |
EP3665270A4 (fr) | 2021-04-21 |
US11648269B2 (en) | 2023-05-16 |
US20230364140A1 (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202000852B (en) | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof | |
IL261941A (en) | Chimeric antigen and t cell receptors and methods of use | |
EP3579877A4 (fr) | Récepteurs antigéniques de lymphocytes t chimériques et leurs procédés d'utilisation | |
IL283734A (en) | Chimeric antigen receptors and car-t cells and methods of use | |
IL257297A (en) | Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them | |
IL280718A (en) | T cell structures and their uses | |
IL284216B (en) | Anti-transferrin receptor antibodies and their uses | |
SG10201913579WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
EP3564266A4 (fr) | Nouveau récepteur chimère de l'antigène et utilisation correspondante | |
DK3365364T3 (da) | Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf | |
EP3645574A4 (fr) | Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation | |
HK1222677A1 (zh) | 特異性嵌合抗原受體重導向性 細胞及其使用方法 | |
HK1256130A1 (zh) | 用於嵌合抗原受體和其他受體的表達的t細胞 | |
IL280029A (en) | ROR-1 specific chimeric antigen receptors and their uses | |
EP3630980A4 (fr) | Préparation cellulaire de récepteurs antigéniques chimériques et utilisations de celle-ci | |
IL286038A (en) | Chimeric antigen receptors directed against cd19 and their use in immunotherapy | |
EP3887509A4 (fr) | Récepteur d'antigène chimère et procédés d'utilisation de celui-ci | |
IL275040A (en) | T cells containing two chimeric receptors for different antigens and their use | |
EP3443076A4 (fr) | Compositions de lymphocytes t à récepteurs alloantigènes chimériques et procédés afférents | |
SG11202101169PA (en) | Chimeric antigen receptor that binds hla-dr and car-t cell | |
ZA202008065B (en) | Muc16 specific chimeric antigen receptors and uses thereof | |
DK3720883T3 (da) | T-celler omfattende kimære anti-cd38- og anti-cd138-antigenreceptorer og anvendelser deraf | |
EP3609536A4 (fr) | Anticorps anti-cd19 humanisé et son utilisation avec un récepteur d'antigène chimère | |
IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
GB2585607B (en) | Chimeric antigen receptor and application thereof |